Bioxodes is a clinical stage biotech company specialized in the development of novel therapeutics using molecules derived from nature to prevent thrombosis and inflammatory processes. 


04/29/2021 - Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI, a drug candidate for the prevention of thrombosis.

Read the full Press Release here.